Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) EV/FCF
As of 16 October 2026, Charles River Laboratories International, Inc. (CRL) trades at a EV/FCF of 45.4×. Over the past ten years it has ranged from 13.0× (April 2025) to 56.0× (October 2021); the current reading is higher than 90% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 22.8× | (0.91%) |
| FY2024 | 23.0× | (41.55%) |
| FY2023 | 39.3× | (14.53%) |
| FY2022 | 46.0× | 14.38% |
| FY2021 | 40.2× | 8.20% |
| FY2020 | 37.2× | 39.20% |
| FY2019 | 26.7× | 16.58% |
| FY2018 | 22.9× | (13.40%) |
| FY2017 | 26.5× | 46.80% |
| FY2016 | 18.0× | (2.06%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 35.9× | 28.82% |
| Mar 2026 | 27.9× | 22.48% |
| Dec 2025 | 22.8× | 27.94% |
| Sep 2025 | 17.8× | 7.19% |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TWST Twist Bioscience Corporation compare | −85.1× |
| GH Guardant Health, Inc. compare | −83.1× |
| ICLR ICON PLC compare | 17.6× |
| DGX Quest Diagnostics Incorporated compare | 23.1× |
| QGEN QIAGEN N.V. compare | 23.5× |
| MEDP Medpace Holdings, Inc. compare | 24.1× |
| LH Labcorp Holdings Inc. compare | 30.8× |
| RVTY Revvity Inc. compare | 34.0× |
| CRL Charles River Laboratories International, Inc. | 45.4× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement